Marina Biotech wie gehts weiter nach Reversesplit?? - 500 Beiträge pro Seite

[zuzlhuba]

Company News
MRNAD MRNAD
Marina Biotech, Inc. NASDAQ-GM




Back to Headlines | Print Version | ShareThis



Marina Biotech Announces $5 Million Private Placement


Implements Reverse Stock Split to Support Financing


BOTHELL, WA -- (MARKET WIRE) -- 12/23/11 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that it has entered into a $5 million private placement with Socius CG II, Ltd. ("Socius"), a Bermuda-based subsidiary of Socius Capital Group, LLC, and that it filed an amendment to its certificate of incorporation to effect a 1-for-10 reverse split of its common stock as of 5:00 p.m. EST on December 22, 2011.

"In an extremely challenging economic environment, we are pleased to continue to have the necessary financial resources to advance our industry-leading science and technology," stated J. Michael French, President and CEO of Marina Biotech. "With this additional funding, we will continue to move CEQ508 rapidly through clinical development with the goal of advancing a treatment for patients with Familial Adenomatous Polyposis quickly to the market. We are also having significant success in the development of microRNA-based therapeutics via both systemic and oral delivery and we look forward to partnering our capabilities in this area. Additionally, the reverse stock split, approved by the shareholders at our annual meeting in July, provides the Company with the authorized shares necessary to complete the placement and to execute potential future transactions with Socius or other partners as well as M&A opportunities."

Under the terms of the Securities Purchase Agreement, the Company has the right, in its sole discretion, over a term of two (2) years and subject to certain closing conditions and limitations, to sell to Socius up to a total of $5 million of redeemable Series B Preferred Stock of the Company (the "Preferred Stock"). The Preferred Stock will accrue a 10% dividend per annum from the date of issuance. Pursuant to the Securities Purchase Agreement, in addition to the Preferred Stock, Socius shall receive an Additional Investment Right and a Warrant, each to purchase shares of the Company's common stock.

When Preferred Stock is sold, Socius is obligated to exercise the Additional Investment Right and purchase a number of shares of common stock equal in dollar amount to 100% of the amount of Preferred Stock purchased at a per share price equal to the closing bid price of the common stock on the most recently completed trading day prior to the time that notice was delivered. Additionally, Socius is obligated to exercise a portion of the Warrant equal to a number of shares calculated by dividing (1) 35% of the dollar amount of Preferred Stock purchased by (2) the closing bid price of the common stock for the most recently completed trading day prior to the delivery of the notice.

Upon exercise, Socius must pay for the shares underlying the Additional Investment Right and the Warrant, at its option, either in cash or by delivering a full-recourse secured promissory note. Any such promissory note will bear interest at 2.0% per year calculated on a simple interest basis and be secured by securities (other than certain securities of the Company) owned by Socius with a fair market value equal to the principal amount of the promissory note.

The Company may redeem the Preferred Stock at any time and, at the option of either the Company or Socius, all outstanding promissory notes may be offset, exchanged and cancelled for all outstanding shares of Preferred Stock then held by Socius. The Preferred Stock is not convertible into shares of common stock and neither the Additional Investment Right nor the Warrant will be listed on any national securities exchange.

In order to facilitate the private placement, the Company filed an amendment to its certificate of incorporation to effect the 1-for-10 reverse split of its common stock. Marina Biotech's common stock will continue trading on the NASDAQ Global Market under the ticker symbol "MRNA", although the letter "D" will be temporarily appended to the ticker symbol for twenty trading days following the reverse split. The common stock will begin trading on a split-adjusted basis at the open of trading on Friday, December 23, 2011.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs: bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Marina Biotech, Inc.
Philip Ranker
Interim Chief Financial Officer
[phone]
[e-mail]: Marina Biotech, Inc.





Latest "In Focus" News Stories

Payroll tax 'compromise' builds uncertainty.
Dec 23, 2011

Fresh tensions unsettle the Falklands
Dec 22, 2011

Court sides with Apple against HTC in UI patent dispute
Dec 20, 2011

Extra capital requirements hammer bank stocks
Dec 19, 2011

Trillion Dollar Baby: Lockheed, Boeing and the JSF
Dec 15, 2011




Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…

[zuzlhuba]

Marina Biotech and Mirna Therapeutics Announce License Agreement for the Development of microRNA-Based Therapeutics


Mirna Therapeutics Will Develop Oncology-Focused Compounds Utilizing Their Proprietary microRNAs Combined With Marina Biotech's Novel SMARTICLES(R) Liposomal Delivery Technology


BOTHELL, WA and AUSTIN, TX -- (MARKET WIRE) -- 12/23/11 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc. (Mirna), a privately-held biotechnology company pioneering microRNA (miRNA) replacement therapy for cancer, announced today that they have entered into a license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology. Mirna will have full responsibility for the development and commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $63 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration. Further terms of the Agreement were not disclosed.

"Given the challenge of effectively delivering oligonucleotides to target tissues, we devoted considerable effort to identifying an optimal delivery technology that would allow for systemic administration of our potent miRNA tumor suppressors and which is already in clinical testing," said Paul Lammers, M.D., M.Sc., President and CEO of Mirna Therapeutics. "With the dramatic in vivo results achieved with our miRNA mimics, we believe the SMARTICLES technology solves the delivery challenge for us, and we are now looking forward to bringing our miRNA mimics into the clinic in the next 18 months as promising targeted cancer therapeutics."

"We are extremely pleased to have entered into this relationship with a company as well respected in the area of microRNA-based therapeutics as Mirna Therapeutics," stated J. Michael French, President and CEO of Marina Biotech. "We are excited to see the continued advancement of oligonucleotide-based therapeutics and to be able to provide a technology capable of effectively delivering, in this case, systemically administered miRNA mimetics. We look forward to the rapid advancement of Mirna Therapeutics' clinical pipeline and the opportunity to bring novel therapeutics to patients in need."

In a recent poster entitled "The Development of a miRNA-based Therapeutic Candidate for Hepatocellular Carcinoma," presented at the November, 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA, Mirna scientists showed that mimics of five tumor suppressor miRNAs, including miR-34 and let-7, all significantly inhibited the growth of liver tumors compared to animals treated with formulated negative control miRNAs. The five miRNA mimics were complexed with Marina Biotech's SMARTICLES delivery formulation and injected into NOD/SCID mice with orthotopically grown Hep3B human liver cancer xenografts.

The companies will present their respective science and technologies at the upcoming Biotech Showcase™ 2012, January 9-11, 2012 at the Parc 55 Wyndham San Francisco - Union Square at 55 Cyril Magnin Street, San Francisco, CA. Mirna Therapeutics will present on Monday, 9 January at 3:00 pm and Marina Biotech will present on Tuesday, 10 January at 2:30 pm.



Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…

[VanGillen]

Was Die Amis eben so am besten können.Geld splitten,so lange bis nix mehr da is.

[zuzlhuba]

Company News
MRNAD MRNAD
Marina Biotech, Inc. NASDAQ-GM




Back to Headlines | Print Version | ShareThis



Marina Biotech, Inc. to Present at Biotech Showcase 2012


Company Will Update on Recent Licensing Transaction and Near-Term Value Drivers


BOTHELL, WA -- (MARKET WIRE) -- 01/03/12 -- Marina Biotech, Inc. (NASDAQ: MRNAD), a leading oligonucleotide-based drug discovery and development company, announced today that it will present at Biotech Showcase 2012 on Tuesday, January 10, 2012, at 5:30 p.m. Eastern Time (2:30 p.m. Pacific Time) at the Parc 55 Wyndham San Francisco in San Francisco. J. Michael French, Marina Biotech President and Chief Executive Officer, will present a corporate overview, the recent Mirna Therapeutics licensing agreement and near-term value drivers.

A live audio webcast will be available on the Event Calendar pages of the Investors section of the Company's website at http://www.marinabio.com. Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the Marina Biotech website under Event Calendar approximately one hour after the live presentation.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company, focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Contact:
Marina Biotech, Inc.
Phil Ranker
Interim Chief Financial Officer
[phone]
[e-mail]: Marina Biotech, Inc.







Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…

[zuzlhuba]

January 6, 2012 - 6:30 AM EST

closeEmail this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

MRNAD 0.86 0.003

Today 5d 1m 3m 1y 5y 10y



Marina Biotech, Inc. Closes Previously Announced $5 Million Financing
http://media.marketwire.com/attachments/201102/20242_mwuploa…
BOTHELL, WA -- (Marketwire) -- 01/06/12 -- Marina Biotech, Inc. (NASDAQ: MRNAD), a leading oligonucleotide-based drug discovery and development company, announced today that it has completed the closing of the previously announced equity investment of up to $5 million with Socius CG II, Ltd. ("Socius"), a Bermuda-based subsidiary of Socius Capital Group, LLC, and will be filing a registration statement on Form S-3 to register the shares for resale by Socius. Once the S-3 is filed and declared effective by the U. S. Securities and Exchange Commission, and subject to the satisfaction of the other conditions set forth in the Securities Purchase Agreement between the Company and Socius, the funds available under the agreement will be accessible by the Company.

"This unique financing structure permits us to access funds as they are required in the near future," stated J. Michael French, President and Chief Executive Officer at Marina Biotech, Inc. "With what we believe is the most unique and broadest nucleic acid drug discovery platform in the industry, we want to ensure we have the necessary funds to continue to execute on our business strategy. In 2011, we established ourselves broadly across the oligonucleotide therapeutic space with two technology deals (an RNAi drug discovery partnership with The Debiopharm Group and a microRNA delivery license with Mirna Therapeutics) as well as two separate nucleic acid technologies in clinical development (liposomal delivery of a single-stranded DNA through a license with ProNAi Therapeutics and our own on-going START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial with CEQ508). We feel access to these funds will give us the necessary financial flexibility to continue to execute on our pre-clinical, clinical and partnering objectives."

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company, focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Contact:
Marina Biotech, Inc.
Phil Ranker
Interim Chief Financial Officer
[phone]
[e-mail]






Source: Marketwire (January 6, 2012 - 6:30 AM EST)

News by QuoteMedia

[zuzlhuba]

Company News
MRNAD MRNAD
Marina Biotech, Inc. NASDAQ-GM




Back to Headlines | Print Version | ShareThis



Marina Biotech, Inc. Provides Update on Its Broad Nucleic Acid-Based Drug Discovery Platform and 2012 Goals


Through Partnership and Licensing Agreements, Marina Biotech's Drug Discovery Platform Brought in Over $1.5 MM in Non-Dilutive Capital in the Fourth Quarter of 2011


BOTHELL, WA -- (MARKET WIRE) -- 01/10/12 -- Marina Biotech, Inc. (NASDAQ: MRNAD), a leading oligonucleotide-based drug discovery and development company, will provide an update on its nucleic acid-based drug discovery platform and 2012 goals at Biotech Showcase 2012 on Tuesday, January 10, 2012, at 5:30 p.m. Eastern Time (2:30 p.m. Pacific Time) at the Parc 55 Wyndham San Francisco in San Francisco.

"In 2011, I believe we established ourselves as the company with the broadest and most comprehensive nucleic acid-based therapeutics drug discovery platform in the industry," stated J. Michael French, President and CEO of Marina Biotech. "The company's broad platform includes an array of unique nucleic acid constructs, chemistries and delivery technologies that offer the diversity and innovation needed to drug historically undruggable targets through a variety of mechanisms of action including RNAi, mRNA translational inhibition, and steric blocking. This capability permits us to identify multiple, distinct therapeutic approaches allowing our partners to be focused on the target not the technology."

Mr. French continued, "In the last quarter alone, we brought in over $1.5 MM of non-dilutive capital from partnerships and licensing agreements. In 2011, I believe we were the only company to complete two deals in two distinct oligonucleotide therapeutic areas: RNAi and microRNA. In addition, we are the only company with two different technologies in clinical development pursuing two different oligonucleotide therapeutic approaches: RNAi and DNAi. Our goals in 2012 are very straightforward, continue to broaden our drug discovery platform through licenses and partnerships and advance our preclinical and clinical programs. I am encouraged by not only our own progress but that of the entire sector and believe that 2012 will be an important year for Marina Biotech as well as the nucleic acid-based therapeutics field."

In 2011, the Company established one of the industry's broadest nucleic acid-based drug discovery platforms:

Two technologies partnered/licensed in two different oligonucleotide therapeutic areas: UsiRNA™ in DiLA2™ liposomal delivery via local administration and microRNA mimics in SMARTICLES® liposomal delivery via systemic administration




Two technologies in clinical development: shRNA delivered via a bacterial vector (tkRNAi™) in the treatment of Familial Adenomatous Polyposis and a single-stranded DNAi via SMARTICLES in the treatment of solid tumors




Marina Biotech's 2012 Goals include:

Continued pursuit of strategic transactions including preclinical and clinical nucleic acid-based programs, additional delivery technologies and microRNA intellectual property




Licensing of proprietary Unlocked Nucleobase Analog (UNA™) and Conformationally Restricted Nucleotide (CRN™) chemistries in the human, veterinary and agricultural fields as well as reagent and diagnostic areas




Licensing of proprietary delivery technologies, including SMARTICLES, for the delivery of double and single-stranded nucleic acids




Completing the Dose Escalating portion of the START-FAP Clinical Trial




Establishing pharma collaboration(s) around multiple targets and therapeutic indications




About Marina Biotech, Inc.

Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. In addition, Marina Biotech has recently entered into an agreement with Mirna Therapeutics to license its SMARTICLES® technology for the delivery of microRNA mimics. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Marina Biotech, Inc.
Philip Ranker
Interim Chief Financial Officer
[phone]
[e-mail]: Marina Biotech, Inc.







Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…

[zuzlhuba]

Marina Biotech To Present At Biotech Showcase; Webcast At 5:30 PM ET



(RTTNews.com) - Marina Biotech Inc. (MRNAD) will present at the Biotech Showcase 2012 Conference in San Francisco.

The event is scheduled to begin at 5:30 PM ET on January 10, 2012.

To access the live webcast, visit www.marinabio.com

For comments and feedback: contact [e-mail]

http://www.rttnews.com




Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…

[zuzlhuba]

hat jeder zufällig reingehört?

[zuzlhuba]

sorry hat jemand in den webcast reingehört?

[zuzlhuba]

zumindestens war der Anstieg gestern nicht übel

[zuzlhuba]

mal sehen ob es heute weiter geht

[zuzlhuba]

Marina Biotech Receives Notice of Acceptance for Patent Broadly Covering Its Unlocked Nucleobase Analog (UNA) Technology


Patent Protects Use of UNAs in Multiple Nucleic Acid Constructs Including siRNAs, microRNA Mimics, Antagomirs and Single-Stranded Constructs


BOTHELL, WA -- (MARKET WIRE) -- 01/23/12 -- Marina Biotech, Inc. (NASDAQ: MRNAD), a leading oligonucleotide-based drug discovery and development company today announced that the Intellectual Property Office of New Zealand (IPONZ) has issued a Notice of Acceptance for patent application 580712. The claims broadly cover multiple sequence independent and length independent, nucleic acid constructs having one or more unlocked nucleobase analogs (UNAs). The nucleic acid constructs of the patent include both RISC and dicer length siRNAs, both microRNA mimetics and microRNA antagomirs as well as single-stranded oligonucleotides.

"The company continues to deliver on a patent strategy which expands and protects our broad oligonucleotide therapeutics platform," stated J. Michael French, President and CEO at Marina Biotech. "This allowed patent is part of our global UNA patent portfolio providing broad and comprehensive protection for multiple, distinct UNA containing nucleic acid constructs all of which can modulate gene expression through distinct cellular mechanisms including RNAi, mRNA translational inhibition, steric blocking or microRNA pathways. This patent allowance reinforces our belief that we will continue to obtain patent protection for our UNA technology in other countries thereby strengthening the company's intellectual property position for our broad oligonucleotide drug discovery platform."

UNA are non-nucleotide, acyclic monomers which provide greater structural flexibility in a nucleic acid strand. Their value has been demonstrated in Marina Biotech's proprietary UsiRNA constructs which are double-stranded small interfering RNA (siRNA) incorporating at least one UNA monomer and are distinct from the standard siRNA constructs used by others in the industry. UsiRNAs are specifically designed to provide greater specificity for RNAi-based therapeutics. Substitution with UNA in the passenger strand (non-targeting strand) is intended to eliminate its participation in the RNAi process. Substitution in the guide strand (targeting strand) is intended to eliminate miRNA-like events, while preserving high siRNA-like activity. Optimization of UNA substitutions in siRNA has previously been published by Merck & Co. (Nucleic Acids Res. 2010 38 (2): 660-671) and Marina Biotech (Nucleic Acids Res. 2011 Mar;39(5):1823-32).

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. In addition, Marina Biotech has recently entered into an agreement with Mirna Therapeutics to license its SMARTICLES® technology for the delivery of microRNA mimics. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Marina Biotech, Inc.
Philip Ranker
Interim Chief Financial Officer
[phone]
[e-mail]: Marina Biotech, Inc.

[zuzlhuba]

Marina Biotech Starts Cohort 2 of Its Phase 1b START-FAP Clinical Trial of CEQ508


Data Review Committee Determines CEQ508 Well Tolerated in Cohort 1 Patients


BOTHELL, WA -- (MARKET WIRE) -- 01/25/12 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that Cohort 2 in the Dose Escalation Phase of the START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial with CEQ508 will begin enrolling patients in the next several weeks at Massachusetts General Hospital (MGH) in Boston. The Company also noted that it has successfully transferred all GMP-related stability testing to a contract services organization.

"Three patients completed Cohort 1 of the study last year," stated Alan W. Dunton, M.D., Consulting Chief Medical Officer at Marina Biotech. "CEQ508 was well tolerated by patients with FAP and the Data Review Committee, comprised of the Principal Investigator, Co-Investigator and myself, unanimously agreed that the study should proceed to Cohort 2. CEQ508 has the potential to be a safe and efficacious therapeutic for a patient population with no currently approved pharmaceutical alternative."

"We are encouraged by the positive safety results from the first cohort and the advancement this represents for CEQ508 and the tkRNAi platform overall," stated Richard Ho M.D.-Ph.D., Executive Vice President, Research and Development at Marina Biotech. "The oral delivery of CEQ508, a highly potent oligonucleotide therapeutic, is unique in the RNAi and nucleic acid space. As proper for a Phase I study and a first-in-class therapeutic, the Cohort 1 dose level is below that expected to result in robust inhibition of beta-catenin messenger RNA, the gene target for CEQ508. However, data collected for Cohort 1 indicates the potential for exposure of CEQ508 throughout the entire intestinal tract which is important for not only FAP but any disease that involves the gastrointestinal system. We look forward to collecting additional safety data in Cohort 2."

About CEQ508

CEQ508 is the first drug candidate in a novel class of therapeutic agents utilizing the transkingdom RNA interference (tkRNAi) platform. CEQ508 comprises attenuated bacteria that are engineered to enter into dysplastic tissue and release a payload of short-hairpin RNA (shRNA), a mediator in the RNAi pathway. The shRNA targets the mRNA of beta-catenin, which is known to be dysregulated in classical FAP. CEQ508 is being developed as an orally administered treatment to reduce the levels of beta-catenin protein in the epithelial cells of the small and large intestine. Upon enrollment, patients will be placed in one of four dose-escalating cohorts. Following completion of the dose escalation phase, the trial plan calls for a stable-dose phase in which additional patients will receive the highest safe dose. CEQ508 will be administered daily in an oral suspension for 28 consecutive days. For more information please contact [e-mail].

About FAP

CEQ508 is being developed for the treatment of Familial Adenomatous Polyposis (FAP), a hereditary condition that occurs in approximately 1:10,000 persons worldwide. FAP is caused by mutations in the Adenomatous Polyposis Coli (APC) gene. As a result of these mutations, epithelial cells lining the intestinal tract have increased levels of the protein beta-catenin, which in turn, results in uncontrolled cell growth. Proliferation of the epithelial cells results in the formation of numerous (hundreds to thousands) non-cancerous growths (polyps) throughout the large intestine. By age 35, 95% of individuals with FAP have developed polyps and most will experience adverse effects including increased risk of bleeding and the potential for anemia. In more severe cases, obstruction of the intestines, abdominal pain, and severe bouts of diarrhea or constipation can occur. FAP patients are also at an increased risk of various cancers, the most concerning of which is a nearly 100% occurrence of colon cancer if measures are not taken to prevent the formation of polyps. For many patients, complete colectomy (surgical removal of the entire large intestine), usually performed in the late teenage years or early twenties, is the only viable option for treatment. However, surgical intervention is not curative as the risk of polyps forming in the remaining portions of the intestinal tract and in the small intestine continues after colectomy.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. In addition, Marina Biotech has recently entered into an agreement with Mirna Therapeutics to license its SMARTICLES® technology for the delivery of microRNA mimics. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

[zuzlhuba]

February 10, 2012 - 6:30 AM EST

closeEmail this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

MRNA 0.4503 -0.0497

Today 5d 1m 3m 1y 5y 10y



Marina Biotech Announces Closing of $1.5 MM Bridge Loan
http://media.marketwire.com/attachments/201102/20242_mwuploa…
BOTHELL, WA -- (Marketwire) -- 02/10/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced the closing of a bridge loan pursuant to a Note and Warrant Purchase Agreement. Under the terms of the loan, the Company sold promissory notes in the aggregate principal amount of $1.5 million and issued warrants to purchase an aggregate of approximately 3.7 million shares of the Company's common stock at $0.508 per share to certain accredited investors.

"As we continue to execute on our business strategy, this capital allows us necessary resources to achieve our first quarter objectives and provides us with the flexibility to pursue certain near-term partnering and financing options," said J. Michael French, President and CEO of Marina Biotech.

The loan will become due and payable on May 14, 2012, with interest calculated at 15% per annum and payable on the due date. The loan is to be secured against the assets of Marina Biotech, Inc. and its subsidiaries.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. In addition, Marina Biotech has recently entered into an agreement with Mirna Therapeutics to license its SMARTICLES® technology for the delivery of microRNA mimics. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Marina Biotech, Inc.
Philip Ranker
Interim Chief Financial Officer
[phone]
[e-mail]






Source: Marketwire (February 10, 2012 - 6:30 AM EST)

News by QuoteMedia

[zuzlhuba]

February 14, 2012 - 6:30 AM EST

closeEmail this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

MRNA 0.4503 -0.0497

Today 5d 1m 3m 1y 5y 10y



Marina Biotech Announces Closure of Cambridge Site and Consolidation of R&D Operations in Bothell, WA
http://media.marketwire.com/attachments/201102/20242_mwuploa…
BOTHELL, WA -- (Marketwire) -- 02/14/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced the closure of its Cambridge site and the consolidation of all research and development efforts at its headquarters in Bothell, WA. In addition, the Company announced dosing of the first patient in Cohort 2 in the Dose Escalation Phase of the START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial with CEQ508.

"After considerable review, we have decided to close our Cambridge site and transfer those research and development efforts to our headquarters in Bothell, WA," said J. Michael French, President & CEO of Marina Biotech. "This move will not affect the START-FAP trial as noted by our announcement today of Cohort 2 dosing. Further, we expect to continue to develop the tkRNAi platform in our labs in Bothell. The closing of the Cambridge site is consistent with our continued efforts to reduce our cash utilization. The individuals affected by this decision were all part of the former Cequent team who then, and certainly over the past several years, were instrumental to the development of CEQ508 and the successful execution of the START-FAP trial. I want to thank them for their efforts and wish them all well in their future endeavors."

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. In addition, Marina Biotech has recently entered into an agreement with Mirna Therapeutics to license Marina Biotech's SMARTICLES® technology for the delivery of Mirna Therapeutics' microRNA mimics. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Marina Biotech, Inc.
Philip Ranker
Interim Chief Financial Officer
[phone]
[e-mail]






Source: Marketwire (February 14, 2012 - 6:30 AM EST)

News by QuoteMedia

[Andrija]

Antwort auf Beitrag Nr.: 42.748.081 von zuzlhuba am 14.02.12 14:18:54

Du postest hier so fleißig...bist Du wirklich investiert. Ich habe noch ein paar Nastechreste mit 99,99% Verlust. Der größte Kapitalvernichter aller Zeiten.

Was bewegt Dich hier zu posten?

[zuzlhuba]

February 22, 2012 - 6:30 AM EST

closeEmail this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

MRNA 0.46 0.025

Today 5d 1m 3m 1y 5y 10y



Marina Biotech Receives Notice of Allowance for U.S. Patent Related to Its Lipid Based Nucleic Acid Drug Delivery Platform
http://media.marketwire.com/attachments/201102/20242_mwuploa…
BOTHELL, WA -- (Marketwire) -- 02/22/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 10/505,107 with claims that broadly cover a library of nucleic acid delivery lipids related to its SMARTICLES® delivery technology. The SMARTICLES delivery technology has been licensed to ProNAi Therapeutics, Inc. for delivery of single-stranded oligonucleotide therapeutics and to Mirna Therapeutics, Inc. for delivery of double-stranded microRNA mimics. The company's library of patent protected delivery compounds includes both DiLA2 and SMARTICLES-based compounds, such as sterol derivatives and two-tailed lipids.

"Our extensive library of delivery compounds provides a large and diverse chemistry space within which we can develop specific delivery formulations tailored to a nucleic acid payload, gene target, and therapeutic indication," stated Richard Ho, M.D., Ph.D., Executive Vice President, Research and Development at Marina Biotech. "Combined with the company's proprietary method for screening large numbers of lipids as well as liposomal compositions, we can quickly identify potent and well tolerated formulations for lead selection. This provides us with a unique ability to offer partners a broad approach to nucleic acid drug discovery and development. We are currently applying our delivery technologies, both DiLA2 and SMARTICLES, in both in-house preclinical efforts as well as through licensing collaborations with The Debiopharm Group and Mirna Therapeutics respectively. This patent is part of our larger global portfolio of delivery compound patents, which ensures the broadest patent protection available to us for our nucleic acid delivery development efforts."

About Marina Biotech, Inc.
Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. In addition, Marina Biotech has entered into an agreement with Mirna Therapeutics to license Marina Biotech's SMARTICLES® technology for the delivery of Mirna Therapeutics' microRNA mimics. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Marina Biotech, Inc.
Philip Ranker
Interim Chief Financial Officer
[phone]
[e-mail]






Source: Marketwire (February 22, 2012 - 6:30 AM EST)

News by QuoteMedia

[zuzlhuba]

February 29, 2012 - 7:30 AM EST

closeEmail this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

MRNA 0.48 -0.03

Today 5d 1m 3m 1y 5y 10y



Marina Biotech Presents Advances in Oral Delivery of Nucleic Acids at AsiaTIDES Conference in Tokyo
http://media.marketwire.com/attachments/201102/20242_mwuploa…
BOTHELL, WA -- (Marketwire) -- 02/29/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today reported data demonstrating the continued advancement of the Company's clinical program for CEQ508, the only orally administered RNAi therapeutic in clinical development. Data were also presented on early research in the oral administration of single- and double-stranded nucleic acids. The data were presented by Michael V. Templin, Ph.D., Senior Vice President and Chief Technology Officer at Marina Biotech, Inc., and entitled "Advances in the Development of Orally Administered Nucleic Acid-based Therapeutics," at AsiaTIDES, Oligonucleotide and Peptide® Research, Technology and Product Development, February 28 - March 1, 2012 in Tokyo, Japan.

"We continue to advance our clinical development program, and we believe that CEQ508 will not only be the first orally delivered nucleic acid in the market but potentially the first RNAi drug to market," stated Richard T. Ho, M.D., Ph.D., Executive Vice President, Research and Development. "The current drug product can be stored for extended time periods in home freezers or refrigerators allowing us the option of bringing a liquid formulation to market and thus minimizing the clinical development cycle. CEQ508 represents the first generation of tkRNAi™, and we are now focused on the development of second generation technology which is expected to provide us a platform for cell specific targeting throughout the entire gastrointestinal tract to treat both inflammatory and oncology diseases. In addition to the tkRNAi system, we are developing alternative methods to oligonucleotide therapeutic delivery via oral administration which dramatically improve both systemic exposure and bioavailability in a variety of tissue systems. Oral administration of oligonucleotide therapeutics as well as new efforts in harnessing cell-to-cell transfer of nucleic acids will be active areas for our research and development team in the immediate future."

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. In addition, Marina Biotech has entered into an agreement with Mirna Therapeutics to license Marina Biotech's SMARTICLES® technology for the delivery of microRNA mimics. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Marina Biotech, Inc.
Philip Ranker
Interim Chief Financial Officer
[phone]
[e-mail]






Source: Marketwire (February 29, 2012 - 7:30 AM EST)

News by QuoteMedia

[zuzlhuba]

March 14, 2012 - 6:30 AM EDT

closeEmail this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

MRNA 0.50 0.00

Today 5d 1m 3m 1y 5y 10y



Marina Biotech and ProNAi Therapeutics Announce License Agreement for the Development of DNAi-Based Therapeutics
http://media.marketwire.com/attachments/201203/41899_pronail…
BOTHELL, WA and ANN ARBOR, MI -- (Marketwire) -- 03/14/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, and ProNAi Therapeutics, Inc. (ProNAi), a privately-held biotechnology company pioneering DNA interference (DNAi) therapies for cancer, announced today that the Companies have entered into an Exclusive License Agreement regarding the development and commercialization of DNAi-based therapeutics utilizing Marina Biotech's novel SMARTICLES® liposomal delivery technology. ProNAi will have full responsibility for the development and commercialization of any products arising under the Agreement. Under terms of the Agreement, Marina Biotech could receive up to $14 million for each gene target in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, with ProNAi having the option to select any number of additional gene targets. For example, if ProNAi licenses five products over time under this Agreement, Marina Biotech could receive up to $70 million in total milestones, plus royalties. Further terms of the Agreement were not disclosed.

"We are pleased that twenty-two patients have been dosed with PNT2258 in our Phase I clinical trial in advanced solid tumor patients to evaluate safety and tolerability, maximum tolerated dose, pharmacokinetics and pharmacodynamics. PNT2258 is our first DNAi oligonucleotide targeted against the anti-apoptotic bcl-2 oncogene and encapsulated in Marina's SMARTICLES® technology. This novel delivery technology offers protection for the DNAi oligonucleotide during systemic administration with good circulation times and extrahepatic tumor exposure. DNAi are short single-strand unmodified oligonucleotides designed to silence genes by interfering with DNA. The DNAi silencing approach is differentiated from that of RNAi, antisense or miRNA in that it targets genomic sequences within the noncoding region of DNA disrupting transcription. The progress and delivery validation in the clinic this past year on the novel DNAi-SMARTICLES® formulation gives us confidence to bring forward more first-in-class drug candidates alone or with partners. ProNAi is now positioned to advance additional cancer therapies from its pre-clinical leads targeting other oncogenes such as c-myc and k-ras while also exploring other disease targets in areas such as inflammation and genetics diseases," said Charles L. Bisgaier, Ph.D., President and CEO of ProNAi Therapeutics.

"We are extremely pleased to have entered into a relationship with a company like ProNAi that is developing a first-in-class nucleic acid therapeutic," stated J. Michael French, President and CEO of Marina Biotech. "In addition, we are excited to see the continued advancement of oligonucleotide-based therapeutics using our SMARTICLES® technology. Besides advancements within our own internal research programs, we have now been able to establish two license agreements broadening the application of the SMARTICLES® technology to the systemic administration of both single- and double-stranded oligonucleotide therapeutics. We look forward to the rapid advancement of ProNAi Therapeutics' clinical pipeline and the opportunity to bring novel therapeutics to patients in need."

ProNAi is conducting an open-label, single arm, Phase I dose-escalation study of PNT2258 in patients with advanced solid tumors for which no standard therapy exists at START in San Antonio, Texas. PNT2258 is ProNAi's first drug candidate from the DNAi drug platform. Patients receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). ProNAi plans to report the results of this Phase I study at oncology conferences later this year and initiate the next Phase I/II safety and efficacy studies in select cancer patients based upon the safety and dose findings from this Phase I study.

About Marina Biotech, Inc.
Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. In addition, Marina Biotech has entered into an agreement with Mirna Therapeutics to license Marina Biotech's SMARTICLES® technology for the delivery of microRNA mimics. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

About ProNAi Therapeutics, Inc.
ProNAi Therapeutics, Inc. is a venture backed, clinical stage, biotech company pioneering a new class of targeted drugs based on utilizing single strands of unmodified DNA oligonucleotides to target genomes responsible for complex, proliferative diseases initially in cancer. The Company's lead drug candidate, PNT2258, has demonstrated safety and in vivo efficacy in a variety of preclinical tumor xenograft models. The Company has successfully raised over $20 million from Apjohn Ventures, Grand Angels, the State of Michigan, Biosciences Research and Commercialization Center (BRCC), Amherst Fund and private investors. Additional information about ProNAi Therapeutics is available at http://www.pronai.com.

Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of ProNAi to obtain additional funding; (ii) the ability of ProNAi Therapeutics to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of ProNAi and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of ProNAi Therapeutics and/or a partner to obtain required governmental approvals; and (v) the ability of ProNAi Therapeutics and/or a partner to develop and commercialize products that can compete favorably with those of competitors.

Marina Biotech, Inc.
Philip Ranker
Interim Chief Financial Officer
[phone]
[e-mail]

ProNAi Therapeutics, Inc.
Wendi Rodrigueza, Ph.D.
Vice President, Product Development
[phone]
[e-mail]

[zuzlhuba]

Marina Biotech und Pronai Therapeutics geben Lizenzvereinbarung für die Förderung der DNAi-basierter Therapeutika

Bellevue, WA und Ann Arbor, MI - (MARKET WIRE) - 03/14/12 - Marina Biotech, Inc. (OTCQX: mRNA), ein führender Nukleinsäure-basierten Wirkstoffforschung und-entwicklung Unternehmen und Pronai Therapeutics, Inc . (Pronai), gab ein im Privatbesitz befindliches Biotechnologieunternehmen, das bahnbrechende DNA-Interferenz (DNAi) Therapien gegen Krebs, dass die beiden Unternehmen haben eine exklusive Lizenzvereinbarung über die Entwicklung und Vermarktung von DNAi-Therapien unter Anwendung Marina Biotech Roman Smarticles ® liposomales eingegeben Delivery-Technologie. Pronai müssen die volle Verantwortung für die Entwicklung und Vermarktung von Produkten aus dem Abkommen. Gemäß den Bedingungen des Abkommens, konnte Marina Biotech erhält bis zu $ ​​14.000.000 für jedes Gen Ziel insgesamt im Voraus, klinische und Vermarktung Meilensteinzahlungen sowie über umsatzabhängige Tantiemen auf den Umsatz, mit Pronai die Option, eine beliebige Anzahl zusätzlicher Gen-Targets auszuwählen. Zum Beispiel, wenn Pronai lizenziert fünf Produkte im Laufe der Zeit im Rahmen dieser Vereinbarung konnte Marina Biotech erhalten bis zu $ ​​70 Millionen in insgesamt Meilensteine ​​sowie Lizenzgebühren. Weitere Einzelheiten der Vereinbarung wurden nicht bekannt.

"Wir freuen uns, dass 22 Patienten mit PNT2258 wurden in unserer Phase-I-Studie dosiert in fortgeschrittenen soliden Tumor-Patienten die Sicherheit und Verträglichkeit, maximal tolerierte Dosis, Pharmakokinetik und Pharmakodynamik zu bewerten. PNT2258 ist unsere erste DNAi Oligonukleotid gegen die Anti-gezielte apoptotischen Bcl-2 Onkogens und verkapselt in Marinas Smarticles ®-Technologie. Dieser Roman Delivery-Technologie bietet Schutz für das DNAi Oligonukleotid während der systemischen Verabreichung mit guter Durchblutung Zeiten und extrahepatische Tumor-Exposition. DNAi sind kurze einsträngige unmodifizierte Oligonukleotide entwickelt, um Gene durch Eingriffe in Schweigen DNA. Die DNAi Silencing Ansatz wird von der RNAi, Antisense-oder miRNA, dass es zielt auf genomischen Sequenzen innerhalb der kodierenden Bereich der DNA-Transkription stören differenziert. Der Fortschritt und Lieferung Validierung in der Klinik im vergangenen Jahr auf dem Roman DNAi-Smarticles ®-Formulierung gibt uns die Zuversicht nach vorne bringen mehr First-in-Class-Wirkstoffkandidaten allein oder mit Partnern. Pronai jetzt positioniert ist, um zusätzliche Krebstherapien aus seiner vorklinischen führt Targeting andere Onkogene wie c-myc-und K-RAS vorrücken lässt dabei auch andere Krankheits-Targets in Bereichen wie Entzündungen und Genetik Krankheiten ", sagte Charles L. Bisgaier, Ph.D., Präsident und CEO von Pronai Therapeutics.

"Wir sind sehr erfreut, in eine Beziehung mit einem Unternehmen wie Pronai dass die Entwicklung einer First-in-Class-Nukleinsäure therapeutischen eingegeben haben", sagte J. Michael Französisch, Präsident und CEO von Marina Biotech. "Darüber hinaus freuen wir uns, die kontinuierliche Fortführung von Oligonukleotid-basierter Therapeutika mit unserem Smarticles ®-Technologie. Neben Neuerungen innerhalb unserer eigenen internen Forschungsprogramme, wir konnten nun zwei Lizenzverträge Verbreiterung der Anwendung der Smarticles etablieren ®-Technologie sehen zur systemischen Verabreichung der beiden Einzel-und doppelsträngige Oligonukleotid Therapeutika. Wir freuen uns auf die rasche Weiterentwicklung der klinischen Pipeline Pronai Therapeutics und die Möglichkeit, neuartige Therapeutika für Patienten in Not zu bringen. "

Pronai führt eine offene, einarmige, Phase I Dosis-Eskalations-Studie der PNT2258 bei Patienten mit fortgeschrittenen soliden Tumoren, für die keine Standardtherapie existiert beim Start in San Antonio, Texas. PNT2258 Pronai ist der erste Medikamentenkandidat aus der DNAi Drogen-Plattform. Die Patienten erhalten PNT2258 als intravenöse Infusion einmal täglich an 5 aufeinanderfolgenden Tagen (Tage 1-5) eines jeden 21-tägigen Zyklus (3 Wochen). Pronai plant, die Ergebnisse dieser Phase-I-Studie bei onkologischen Konferenzen später in diesem Jahr berichten und starten Sie die nächste Phase I / II-Studien die Sicherheit und Wirksamkeit in ausgewählten Krebspatienten auf die Sicherheit und die Dosis Erkenntnisse aus dieser Phase-I-Studie.

Über Marina Biotech, Inc.
Marina Biotech ist ein Biotechnologie-Unternehmen auf die Entwicklung und Vermarktung von Oligonukleotid-basierte Therapien unter Anwendung mehrere Wirkmechanismen einschließlich RNA-Interferenz (RNAi) und Boten-RNA translationale Blockierung konzentriert. Die Marina Biotech-Pipeline umfasst derzeit ein klinisches Programm in familiärer adenomatöser Polyposis (einer präkanzerösen Syndrom) und zwei vorklinische Programme - in Blasenkrebs und malignem Aszites. Marina Biotech hat eine exklusive Vereinbarung mit The Debiopharm Group für die Entwicklung und Vermarktung des Blasenkrebs-Programm. Darüber hinaus hat Marina Biotech eine Vereinbarung mit Mirna Therapeutics zu lizenzieren Marina Biotech Smarticles ®-Technologie für die Lieferung von microRNA Mimik eingetragen. Marina Biotech hat das Ziel, die menschliche Gesundheit durch die Entwicklung von RNAi-und Oligonukleotid-basierte Verbindungen und Drug-Delivery-Technologien, die zusammen eine überlegene therapeutische Optionen für Patienten zu verbessern. Zusätzliche Informationen über Marina Biotech finden Sie unter http://www.marinabio.com.

Über Pronai Therapeutics, Inc.
Pronai Therapeutics, Inc. ist ein durch Risikokapital finanziertes, klinisches Stadium, führendes Biotech-Unternehmen eine neue Klasse von zielgerichteten Medikamenten auf der Nutzung Einzelstränge von unmodifizierten DNA-Oligonukleotide, um Genome verantwortlich für komplexe, proliferativer Erkrankungen zunächst in Krebs-Target basiert. Nach der Durchführung eines Wirkstoffkandidaten, PNT2258, hat die Sicherheit und Wirksamkeit in vivo in einer Vielzahl von präklinischen Tumor Xenograft-Modellen unter Beweis gestellt. Das Unternehmen hat erfolgreich über 20 Millionen Dollar aus Apjohn Ventures, Grand Engel, der Staat Michigan, Forschung und Kommerzialisierung Biosciences Center (BRCC), Amherst Fonds und private Investoren erhöht. Zusätzliche Informationen über Pronai Therapeutics finden Sie unter http://www.pronai.com.

[Andrija]

Zumindest geht es weiter, mit dem Kurs aber wieder abwärts. Dachte schon man könnte etwas verpassen.


Marina Biotech, Inc. to Raise $1.2 Million in Registered Direct Offering

BOTHELL, WA, Mar 19, 2012 (MARKETWIRE via COMTEX) -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, announced that it has entered into definitive agreements with certain institutional investors for a registered direct placement of approximately $1.2 million of common stock at a price of $0.75 per share.

In addition, the Company will issue to the investors warrants to purchase up to 800,000 shares of common stock. The warrants have an exercise price of $0.75 per share and are immediately exercisable for a period of five years. The offering is expected to close on or about March 22, 2012, subject to satisfaction of customary closing conditions.

J. Michael French, President and CEO, stated, "This financing offers us the opportunity to continue to move forward on our near-term business and scientific objectives. We've now licensed our SMARTICLES(R) delivery technology to two companies for the delivery of both double- and single-stranded oligonucleotides. We expect to continue to generate value with our drug discovery platform which we believe is the broadest and most comprehensive nucleic acid discovery engine in the industry."

Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), acted as the exclusive placement agent for the transaction.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-168447), which was declared effective by the United States Securities and Exchange Commission ("SEC") on September 30, 2010. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or by request at Rodman & Renshaw LLC, 1251 Avenue of the Americas, 20th Floor, New York, NY 10020, or by calling 212-356-0549 or e-mailing [e-mail]. p

[zuzlhuba]

April 3, 2012 - 6:30 AM EDT

closeEmail this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

MRNA 0.60 -0.05

Today 5d 1m 3m 1y 5y 10y



Marina Biotech Completes Dosing of Second Cohort in the Phase 1b START-FAP Clinical Trial of CEQ508
http://media.marketwire.com/attachments/201102/20242_mwuploa…
BOTHELL, WA -- (Marketwire) -- 04/03/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced the completion of dosing for Cohort 2 in the Dose Escalation Phase of its START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial with CEQ508. The three patients of Cohort 2 received a dose of 1x10(9) colony forming units (cfu)/day for up to 28 days of continuous oral dosing. Patients were monitored by study staff on a daily basis with the primary study endpoint of determining safety and tolerability of CEQ508 in patients with FAP. Dosing of Cohort 3 is expected to begin later in the second quarter of this year with each patient in the cohort receiving a dose of 1x10(10) cfu/day for up to 28 days.

"We're pleased to announce the completion of dosing of the second patient Cohort and plan to progress to Cohort 3 of our START-FAP trial," stated J. Michael French, President and CEO at Marina Biotech. "Progression through the dose escalation phase will determine the most appropriate once-daily dose for the stable dose phase. We are eager to advance into our next dosing cohort and continue to be on track with our projections of completing the dose escalation phase by the end of the year. We believe CEQ508 has the potential to be a safe and efficacious therapeutic for a patient population with no currently approved pharmaceutical alternative."

About CEQ508

CEQ508 is the first drug candidate in a novel class of therapeutic agents utilizing the transkingdom RNA interference (tkRNAi) platform. CEQ508 comprises attenuated bacteria that are engineered to enter into dysplastic tissue and release a payload of short-hairpin RNA (shRNA), a mediator in the RNAi pathway. The shRNA targets the mRNA of beta-catenin, which is known to be dysregulated in classical FAP. CEQ508 is being developed as an orally administered treatment to reduce the levels of beta-catenin protein in the epithelial cells of the small and large intestine. Upon enrollment, patients will be placed in one of four dose-escalating cohorts. Following completion of the dose escalation phase, the trial plan calls for a stable-dose phase in which additional patients will receive the highest safe dose. CEQ508 will be administered daily in an oral suspension for 28 consecutive days. For more information please contact [e-mail].

About FAP

CEQ508 is being developed for the treatment of Familial Adenomatous Polyposis (FAP), a hereditary condition that occurs in approximately 1:10,000 persons worldwide. FAP is caused by mutations in the Adenomatous Polyposis Coli (APC) gene. As a result of these mutations, epithelial cells lining the intestinal tract have increased levels of the protein beta-catenin, which in turn, results in uncontrolled cell growth. Proliferation of the epithelial cells results in the formation of numerous (hundreds to thousands) non-cancerous growths (polyps) throughout the large intestine. By age 35, 95% of individuals with FAP have developed polyps and most will experience adverse effects including increased risk of bleeding and the potential for anemia. In more severe cases, obstruction of the intestines, abdominal pain, and severe bouts of diarrhea or constipation can occur. FAP patients are also at an increased risk of various cancers, the most concerning of which is a nearly 100% occurrence of colon cancer if measures are not taken to prevent the formation of polyps. For many patients, complete colectomy (surgical removal of the entire large intestine), usually performed in the late teenage years or early twenties, is the only viable option for treatment. However, surgical intervention is not curative as the risk of polyps forming in the remaining portions of the intestinal tract and in the small intestine continues after colectomy.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. In addition, Marina Biotech has entered into an agreement with both Mirna Therapeutics and ProNAi Therapeutics to license Marina Biotech's SMARTICLES® technology for the delivery of microRNA mimics and DNAi, respectively. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

[Schlood]

Antwort auf Beitrag Nr.: 42.994.757 von zuzlhuba am 03.04.12 13:24:16

http://finance.yahoo.com/news/marina-biotech-announces-world…

[Schlood]

http://finance.yahoo.com/news/marina-biotech-receives-three-…

[Schlood]

http://finance.yahoo.com/news/marina-biotech-girindus-group-…

[Andrija]

Das wars dann wohl endgültig:

Marina Biotech Ceases Most Day-to-Day Operations
Continues to Seek Substantial Funding and Strategic Opportunities

BOTHELL, WA, Jun 01, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that it does not currently have adequate funding to continue implementing its business plan. To conserve available cash, management has implemented a furlough of approximately 90% of its employees and ceased most day-to-day operations, including the ongoing FAP clinical trial. Additionally, the Company has negotiated an extension on its secured loan, which is now due and payable in its entirety June 15, 2012, through the issuance to the secured lenders of five-year warrants to purchase approximately 425,000 shares of common stock.

The Company has previously engaged banking teams to assist in identifying strategic opportunities and to seek additional funding. Although these efforts are on-going, no assurances may be made as to their success. If sufficient additional funds are not received in the near-term, the Company may need to further reduce or cease operations completely.

Das "Unternehmen" ist derartig intransparent und verbrennt nur Kapital, wer außer "Hard-Core-Zocker sollen da noch investieren? Selbst wenn die "den" Blockbuster in der Pipeline hätten, würden die keine dauerhafte Refinanzierung mehr stemmen.

[marusch]

MRNA steht meiner Meinung nach erst am Anfang trotz 400% Anstieg seit ende November!! Die Marktkapitalisierung von 16 mill. ist in diesem Segment einfach lächerlich! Mein persönliches 12Monats Kursziel liegt bei 8-9,5 usd! Die RNAI Technologie wird der Renner 2014 so ich denke!!

[Andrija]

Antwort auf Beitrag Nr.: 46.410.956 von marusch am 09.02.14 16:25:01

Würde mich freuen, dann bin ich nur noch 98% im Minus.

[marusch]

Antwort auf Beitrag Nr.: 46.413.102 von Andrija am 10.02.14 08:28:18

Die RNAI Technologie wurde die letzten 3-4 Jahre nur belächelt,doch jetzt ist sie ziemlich heiß! Bin leider kein Microbiologe doch in andere Foren setzen viele Fachleute auf Sie. Eine Partnerschaft mit einem Big Player wäre natürlich der große Durchbruch für MARINA.Sie haben sehr vielversprechende Patente im Portfolio so ich denke. keine kaufempfehlung

[marusch]

Antwort auf Beitrag Nr.: 46.453.317 von marusch am 14.02.14 14:11:31

Nettes Infovideo!
http://www.youtube.com/watch?v=DRUh56wYbv8

[marusch]

Antwort auf Beitrag Nr.: 46.459.461 von marusch am 15.02.14 11:10:53

Wahnsinns Chart Heute!

[marusch]

Antwort auf Beitrag Nr.: 46.504.135 von marusch am 21.02.14 18:29:49

Back to Nasdaq?!

[marusch]

Antwort auf Beitrag Nr.: 46.504.291 von marusch am 21.02.14 18:57:51

Kein Interesse in Deutschland an dieser Perle?

[Andrija]

Antwort auf Beitrag Nr.: 46.504.443 von marusch am 21.02.14 19:22:01

Wow der Anstieg ist nicht schlecht. Woran liegt es?

Bin 0,005% weniger im Minus :-(

[dottore]

der Kurs könnte entsprechend der Kapitalerhöhung auf etwa 75 fallen.

Sollte er dann schnell wieder steigen, wäre das eine gute Einstiegschance, wie bei Idera.
Sollte er dann länger unten bleiben, da die Produkte Marktfern sind ... könnte es für den Langfristamleger trotzdem ein interessanter Einstieg werden.
Ich willschon einen Monat einsteigen und tat es nicht, weil der Kurs zu steil anstieg. Jetzt? ... schaun mer mal, was die amis machen ...

[tantegrete13]

Antwort auf Beitrag Nr.: 46.513.129 von dottore am 24.02.14 14:23:57

dottore,
hier ein unbezahlbarer tipp von mir...finger weg von dem mistding!!!

mit minus 99,84% liegt marina biotech als leiche in meinem depot
...damals hies der schuppen noch nastech.

...für einen trade vielleicht geeignet.

tantchen

[marusch]

Antwort auf Beitrag Nr.: 46.513.505 von tantegrete13 am 24.02.14 15:34:59

Zitat von tantegrete13dottore,
hier ein unbezahlbarer tipp von mir...finger weg von dem mistding!!!
Das "Mistding" kennt nur noch eine Richtung!!

[marusch]

Antwort auf Beitrag Nr.: 46.514.605 von marusch am 24.02.14 17:55:41

To the Moon Baby, to the Moon

[Andrija]

Antwort auf Beitrag Nr.: 46.520.527 von marusch am 25.02.14 15:52:58

Du hast das Teil direkt in USA gekauft?

[dottore]

Zitat von dottore: der Kurs könnte entsprechend der Kapitalerhöhung auf etwa 75 fallen.

Sollte er dann schnell wieder steigen, wäre das eine gute Einstiegschance, wie bei Idera.
Sollte er dann länger unten bleiben, da die Produkte Marktfern sind ... könnte es für den Langfristamleger trotzdem ein interessanter Einstieg werden.
Ich willschon einen Monat einsteigen und tat es nicht, weil der Kurs zu steil anstieg. Jetzt? ... schaun mer mal, was die amis machen ...

wenn ich heute den Kurs sehe, war das wohl der Beweis einer kompletten Fehleinschätzung.
Unglaublich, wie der Kurs abgeht.
Wenn ich mich schon vorher nicht traute, dann jetzt noch weniger. Wäre aber schon gern dabei gewesen. :O

[dottore]

naja, so ganz falsch lag ich denn doch nicht. Der Kurs ging ja auf 1,10 zurück. Leider hab ich nicht mehr frauf geachtet und vielleicht hätte ich da auch nicht gekauft.
besser nicht mehr herschauen ...

[tancho]

wie sind die Einschätzungen für die nächste Zeit?

[marusch]

Antwort auf Beitrag Nr.: 46.530.115 von tancho am 26.02.14 20:16:23

Jetzt kaufen und 3 Jahre liegen lasse.

[marusch]

Antwort auf Beitrag Nr.: 46.530.663 von marusch am 26.02.14 21:42:58

Rücksetzer dabei ausnutzen!!

[marusch]

Super News und der Kurs geht weiter runter? Na ja, der Anstieg war dann doch zu steil. Volumen ist aber relativ gering.Wenns morgen noch mal runter geht werd ich meine letzte Posi kaufen.

[Andrija]

Antwort auf Beitrag Nr.: 46.530.663 von marusch am 26.02.14 21:42:58

Wenn Du solche Empfehlungen ausgibst, hast Du Dir über die Kapitalausstattung Gedanken gemacht? Ich habe schon den einen oder anderen Kapitalschnitt hinter mir.

[marusch]

Antwort auf Beitrag Nr.: 46.538.609 von Andrija am 28.02.14 07:04:07

test,test,

[marusch]

Antwort auf Beitrag Nr.: 46.543.801 von marusch am 28.02.14 17:59:07

Kann lange Beiträge nicht einstellen!

[marusch]

Antwort auf Beitrag Nr.: 46.538.609 von Andrija am 28.02.14 07:04:07

Keine Empfehlung, nur meine Einschätzung!

[sufenta]

Antwort auf Beitrag Nr.: 46.543.823 von marusch am 28.02.14 18:01:27

War das der Ausbruch Richtung 10?!

Hab heute das 3.Mal nachgekauft.

Die Aussichten sind grandios!!!

Gruss

[dottore]

kompliment
danke für bm
habe leider im Moment nicht die Mittel zum Kaufen, aber die steigt auch noch weiter, bestimmtbis an die 3 $.
Ich schau gleich mal, ob ich nicht doch was zum Umschichten finde

[marusch]

Antwort auf Beitrag Nr.: 46.606.639 von sufenta am 11.03.14 15:23:06

Hab leider versäumt bei 1,2 nochmal nachzukaufen schade! Chart sieht heute sehr sehr gut aus!!

[marusch]

Chart forMarina Biotech, Inc. (MRNA)

[marusch]

Hot-hotter-MRNA
1,72$

[marusch]

Die Tagescharts von Marina sind manchmal schon sehr verrückt!
Aber noch grün! Die ganze Branche ist ziemlich heiß. TKMR, ALNY,......
Marina steht meiner Meinung erst ganz am Anfang. Die Amis träumen ja schon von 100$ pro Stück! Na ja 10$ wären schon toll. Time will tell

[marusch]

TKMR -9,5% MRNA + 7,7%
Der 3 Monats Chart sieht richtig geil aus!!
Sicher, jeder hätte gerne bei 0,25 gekauft, ich natürlich auch, aber ich denke der Run ist noch lange nicht vorbei. Nur meine Meinung. Marusch

[tantegrete13]

Antwort auf Beitrag Nr.: 46.647.143 von marusch am 17.03.14 21:24:08

einer meiner aktienleichen, 2mal resplit und zwei mal namensänderung....schei..ding
nach jahrelangen forschungen eiert die firma im nirgendwo herum.
alles nur luft und lügen, kein marktreifes produkt

hände weg!!!

tantchen

[marusch]

Antwort auf Beitrag Nr.: 46.648.849 von tantegrete13 am 18.03.14 09:53:47

Auch ich hab Aktienleichen im Depot Tantegrete. Dass kleine Biotech Firmen oft high risk Papiere sind ist jedem klar. Umso wichtiger ist dann der Einstiegszeitpunkt!! Natürlich steckt in MRNA viel Zukunftshoffnung,aber wenns hier funzt, dann richtig! Denke die Patente sind Einzigartig! Ist halt kein DAX-Wert. 700% in 3 Monaten! Hallooo

[marusch]

Ein typischer OTC Zock dauert etwa 3 Tage. Dieser Aufwärtstrend dauert schon mehr als 3 Monate!! lg marusch

[tantegrete13]

lieber marusch, jetzt noch einmal mit zahlen aus meinem depot unterlegt.

kaufpreis 7 500.- euronen, derzeitige depotwert 16,45 euronen (16 aktien)

fundermental hat sich überhaupt nichts geändert.

tantchen

[marusch]

Antwort auf Beitrag Nr.: 46.663.155 von tantegrete13 am 20.03.14 06:24:11

Hy, tantegrete. Ich versteh ja deinen Frust bezüglich MRNA! Fundamental hat sich nicht viel geändert, stimmt. Aber bestimmt die Marktkapitalisierung! Und einige Patente sind auch dazugekommen. Ich bin mit CBAI ordentlich auf die Nase gefallen. Hab damals CBAI bei einer MK von 200mill gekauft. Na ja,4 Jahre später ist man immer gscheiter! Schönen Abend noch. lg Marusch

[marusch]

Eine Frage Tantchen, würd gerne in Brennstoffzellen investieren. Bist du bei Ceramic Fuel Cells dabei? Im Forum hab ich dich entdeckt. Der Kurs würd mich schon sehr jucken! gruß Marusch

[tantegrete13]

in BZ-werten bin ich momentan ziemlich dicke drin.
ich habe meine catoil-position vor ca. 3 wochen vollständig in BZ-werten investiert.
ich bin praktisch ALL IN in BZ-werte investiert.

neben ceramic habe ich noch neah, hypersolar, mantra, plug power und ballard in meinem depot.

aber über diese bz werte sollten wir in den jeweiligen foren diskutieren.

p.s. bei ceramic würde ich noch warten, da noch eine KE unter den jetzigen kursen noch ansteht

[marusch]

WOW!!! Kaum bin ich 2 Wochen auf Urlaub, steigt meine Perle
mehr als 100%. Sollte öfters urlauben!!Lg an alle Longs.

[marusch]

Marina hat eine neue Webseite! Gutes Zeichen!?
lg marusch

[tantegrete13]

Antwort auf Beitrag Nr.: 47.756.469 von marusch am 11.09.14 16:46:52

es geht doch

http://www.wallstreet-online.de/nachricht/6997875-marina-bio…

tantchen

[Popeye82]

Antwort auf Beitrag Nr.: 47.760.885 von tantegrete13 am 12.09.14 05:35:41

Marina Biotech Announces the Continued Worldwide Expansion of Its Delivery Technology Intellectual Property Estate, Patents Covering the Company's SMARTICLES(R), tkRNAi, DILA2 +Lipopeptide Delivery Technologies Are Granted in Europe, Japan, Australia +China, Respectively - Sep 11, 2014
www.marinabio.com/files/8614/1044/9152/14-09-11_-_Marina_Bio…

"BOSTON, MA--(Marketwired - Sep 11, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that it had received patent protection for its comprehensive and diverse nucleic acid delivery platform with patent grants covering the following delivery technologies: SMARTICLES® in Europe; TransKingdom RNA™ interference (tkRNAi) in Japan; Di-terminal Amino Acid Lipids (DILA2) in Australia; and lipopeptide nucleic acid delivery in China. These grants support a global intellectual property estate broadly covering the Company's biochemistry and delivery technologies with over 100 issued or allowed patents and over 90 pending U.S. and foreign patent applications.

"Marina Biotech continues to extend patent coverage for its nucleic acid delivery technologies in key commercial markets," stated J. Michael French, president & CEO of Marina Biotech. "Looking broadly at our nucleic acid delivery capability, we believe we are the only company that has a delivery technology, SMARTICLES, in clinical development that is: (1) delivering both a single-stranded and double-stranded nucleic acid; (2) delivering to both the cell nucleus (ProNAi Therapeutics' single-stranded DNA decoy) and cell cytoplasm (Mirna Therapeutics' double-stranded microRNA mimic); and (3) delivering a lipid nanoparticle outside the liver, (i.e. tumors). Further, we believe we are the only company that has two separate and distinct delivery technologies, SMARTICLES (lipid nanoparticle) and tkRNAi (engineered bacteria), in clinical development. Finally, we are the only company with an orally administered RNAi-based therapeutic in clinical development - the Company's CEQ508 for the treatment of Familial Adenomatous Polyposis. Taken in its entirety, we believe our delivery platform is unparalleled within the sector and unequalled in clinical versatility. We expect these technologies to be instrumental in the rapid advancement of nucleic acid therapeutics treating rare diseases."


SMARTICLES® (Europe)
SMARTICLES are amphoteric liposomes composed of unique combinations of anionic and cationic lipids that work together to enable cell uptake and to provide serum stability and pH-triggered endosomal escape. SMARTICLES is the only technology delivering both single-stranded (PNT2258) and double-stranded (MRX34) nucleic acid payload in ongoing clinical trials conducted by licensees, ProNAi Therapeutics and Mirna Therapeutics, respectively.

The claims of Marina Biotech's patent for licensed SMARTICLES delivery technology in Europe (Ser. No. 10734065.5) cover delivery technology based on SMARTICLES amphoteric liposomes adapted for the release of therapeutic cargos, including the Company's RNA-based therapeutics having conformationally restricted nucleotides (CRN).

TransKingdom RNA™ interference (Japan)
tkRNAi are non-pathogenic bacteria engineered to produce, deliver, and release to targeted tissue various therapeutic molecules including interfering RNA mediators, such as short hairpin RNA and microRNA mimics, as well as other therapeutics. Marina Biotech's tkRNAi technology includes CEQ508, the only orally administered nucleic acid therapeutic in clinical development. CEQ508 has been orally administered in two cohorts of a four cohort dose-escalating study in a Phase 1 human clinical trial in Familial Adenomatous Polyposis (FAP) patients. The Company has received U.S. Food and Drug Administration Orphan Drug Designation for this program.

The claims of Marina Biotech's patent for tkRNAi delivery technology in Japan (Ser. No. 2007-546917) cover a wide range of compositions for bacterial mediated gene silencing, as well as the fundamental invasive bacterium for delivering RNA therapeutics. The patent issuance in Japan will expand the international coverage of this technology, which includes related patents granted in Europe, Korea, Australia and Canada.

Di-terminal Amino Acid Lipids (Australia)
DILA2 are proprietary molecules composed of unique combinations of head groups and terminal groups on a central amino acid having unique cone angles for formation of small, cargo-carrying liposomes. DILA2 technology is designed to improve a variety of delivery characteristics including encapsulation of nanoparticles, cellular uptake, endosomal release, and cell/tissue targeting.

The claims of Marina Biotech's National Stage Application for DILA2 liposomal delivery technology in Australia (Ser. No. 2008247488) broadly cover DILA2 compounds, as well as compositions containing therapeutic nucleic acids, and uses for delivering drugs to cells, tissues, organs, and subjects having a wide range of diseases. The patent claims granted in Australia cover norarginine-based DiLA2 compounds, which are known to be some of the most efficacious liposome-forming compounds developed by Marina Biotech for delivery of nucleic acid-based therapeutics.

Lipopeptide nucleic acid delivery (China)
Marina Biotech's proprietary lipopeptide delivery formulations encompass a novel lipopeptide structure with multiple attachment points that is designed to capture and bind anionic agent while allowing for the release of the agents in the cellular uptake process. In that sense, the lipopeptide formulations reflect a universal delivery technology for nucleic acid-based therapeutics.

The claims of Marina Biotech's patent for lipopeptide delivery technology in China (Ser. No. 200880110140.7) cover delivery technology based on lipopeptides that were developed by Marina Biotech for delivery of nucleic acid-based therapeutics. The granted claims cover lipopeptide formulations that are suitable for carrying and releasing therapeutic cargos such as the company's RNA-based drug candidates having conformationally restricted nucleotides (CRN), as well as other RNA and DNA-based therapeutics.


About Marina Biotech, Inc.

Marina Biotech is an oligonucleotide therapeutics company with broad drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. These technologies were built via a roll-up strategy to discover and develop different types of nucleic acid therapeutics in order to modulate (up or down) a specific protein(s) which is either being produced too much or too little thereby causing a particular disease. We believe that the Marina Biotech technologies have unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases. Further, we believe Marina Biotech is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. Our novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, Monsanto, and Tekmira. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and a preclinical program in myotonic dystrophy. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at www.marinabio.com. ..."

[marusch]

Ein Posting aus dem Yahoo Forum:
Now... Worst case scenario, Marina will be bought out by a large biotech company
at an extremely attractive price to investors.

Best case scenario..... French turns Marina into a multi-billion RNAi biotech giant.

Sentiment: Buy

Das ist auch meine Meinung.
Aber etwas Geduld muss man hier schon aufbringen.
schönes WE marusch

[marusch]

Leider so gut wie kein Volumen momentan. Für mich ein kleines Rätsel. Geduld Longs!

[marusch]

Volumen 9Stück!! Was soll das??!!

[marusch]

Auch wenn´s hier anscheinend keinen mehr interessiert, Ich schau in eine rosige Zukunft mit Marina! Mein persönliches Kursziel in 12 Monate ist 3,8$. Werd im Dezember noch mal nachkaufen. Marusch

[marusch]

Auf geht´s meine Herren!!

[marusch]

Von+21% auf -1% in einer Stunde!! Wow Für mich als "LONG" aber eigentlich uninteressant. Gruß Marusch

[marusch]

Marina Biotech: A Forgotten And Grossly Undervalued Game-Cha…

[marusch]

http://seekingalpha.com/article/2709645-marina-biotech-a-for…

[marusch]

Und das ganze von Seeking Alpha!! Wow!!

[marusch]

MRNA ist definitiv meine Altersvorsorge!

[sufenta]

Antwort auf Beitrag Nr.: 48.411.656 von marusch am 25.11.14 19:05:49

Welche Kursziele ind welchen Zeitraum haben Sie denn?

4,50 wie bei s.a.?

Meine Meinung/Wunsch: bin investiert und warte auf den grossen Hype/Push, wenn die Aktie von der Masse/den Tradern entdeckt und entsprechend auf mehrere Dollar gepusht wird, um dann im Hype zu verkaufen...bis 3...4...5 $

Wie lange gedenken Sie denn zu halten?

Gruss,

s.

[marusch]

3-4 Dollar sind 2015 locker drin, so ich denke.
Momentan hab ich vor Marina 5-10 Jahre zu halten. Aber wer weis das schon.
Könnte aber wirklich was Großes werden mit diesen Patenten! Man braucht viel Geduld bei dem Papier. Gruß Marusch

[marusch]

Volumen lässt leider schon wieder nach. Bin gespannt wann der wirkliche Durchbruch kommt. Möglicherweise sind es noch Jahre, ich kann warten.

[tantegrete13]

Antwort auf Beitrag Nr.: 48.445.227 von marusch am 28.11.14 17:03:36

schritt für schritt...news sind da:

http://www.wallstreet-online.de/nachricht/7258838-marina-bio…

tantchen

[marusch]

Antwort auf Beitrag Nr.: 49.137.170 von tantegrete13 am 21.02.15 14:20:32

Die News ist doch 2 Monate alt: oder?

[marusch]

Jeden Tag einen Cent rauf... ist OK aber dann bitte ein Jahr lang!! wird schon noch werden. Marusch

[tantegrete13]

Antwort auf Beitrag Nr.: 49.141.913 von marusch am 22.02.15 17:24:35

dieser Q-bericht nicht
http://www.wallstreet-online.de/nachricht/7410944-marina-bio…" target="_blank" rel="nofollow ugc noopener">http://www.wallstreet-online.de/nachricht/7410944-marina-bio…


tantchen

[tantegrete13]

Antwort auf Beitrag Nr.: 49.164.053 von marusch am 24.02.15 19:47:00

heute geht´s wieder 3cent richtung süden

tantchen